Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Documentation

  • Home >
  • Investors & media >
  • Documentation
22 April 2025
Regulated information

CONVERTIBLE BONDS ISSUED ON DECEMBER 28, 2022 Open in new window

08 April 2025
Financial statements and reports, Regulated information

URD 2024 Open in new window

29 January 2025
Investor newsletter

Investor Newsletter – January 2025 (English) Open in new window

27 January 2025
Investor newsletter

Investor Newsletter – January 2025 (French) Open in new window

07 January 2025
Regulated information

Monthly Information regarding the total number of voting rights Open in new window

07 January 2025
Regulated information

CONVERTIBLE BONDS ISSUED ON DECEMBER 28, 2022 Open in new window

07 November 2024
Regulated information

Monthly Information regarding the total number of shares Open in new window

31 October 2024
Investor newsletter

Investor Newsletter – October 2024 (French) Open in new window

07 October 2024
Regulated information

MONTHLY INFORMATION REGARDING THE TOTAL OF VOTING RIGHTS Open in new window

07 October 2024
Regulated information

CONVERTIBLE BONDS ISSUED ON DECEMBER 28, 2022 Open in new window

  • View previous 9 articles
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 23
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page